Physician profile
Simranjit Kaur
NPI 1992256226
$2,702.04
in general payments reported to CMS, 2019-2025
18 companies · $670 in 2025
The $670 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $631 · 2023: $291 · 2024: $682 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $374.99 | 2024-2025 | Repatha, Evenity |
| Novo Nordisk INC | $340.84 | 2021-2022 | |
| Lilly USA, LLC | $303.48 | 2021-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $205.89 | 2022-2025 | |
| Abbott Laboratories | $147.17 | 2025 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $139.77 | 2024 | Ingrezza |
| Medtronic, INC. | $130.06 | 2022 | |
| Incyte Corporation | $125.00 | 2023 | Opzelura |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Redhill Biopharma INC. | $124.99 | 2022 | |
| Nestle Healthcare Nutrition INC. | $123.81 | 2021 | |
| Ardelyx, INC. | $123.37 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $122.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.50 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $75.50 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.15 | 2023 | Xifaxan |
| Verrica Pharmaceuticals INC. | $13.00 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simranjit Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.